Among patients who received biologic DMARDs, 8 psoriasis patients and 1 PsA patient received IL-17 blockers, one PsA patient was treated with an IL-23 inhibitor, and another received a TNF-inhibitor (Table 1). The gene discussed is IL17A; the disease is psoriasis.